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Background: Ideal conditions for platelet reactivity testing are critical for optimal selection of a P2Y12 inhibitor.
Data are inconsistent regarding the impact of high-fat meals on test assessment.
Methods: Participants included 12 healthy subjects not taking antiplatelet drugs after a 12-hour fast. After baseline
assessment, subjects were given a 600 mg dose of clopidogrel. Four hours later, maximum platelet inhibition was
tested in the fasting state by light transmission aggregometry (LTA), VerifyNow P2Y12, vasodilator-stimulated
phosphoprotein (VASP), and whole blood aggregometry (WBA). Subjects were then provided a high-fat meal, and
platelet function was evaluated two hours later. Change in measured platelet aggregation by LTA was the primary
endpoint of the study. The Wilcoxon Rank Sum test was used to compare the change in platelet reactivity between
fasting and non-fasting conditions. The Spearman rho (ρ) correlation coefficient was used to evaluate the association
between fasting platelet reactivity and the change following a high-fat meal.
Results: No significant change occurred in maximal light transmission, as assessed by LTA with 5 μM ADP (p = 0.15)
and with 20 μM ADP (p = 0.07). There was a significant change in the area under the curve with 5 μM ADP (p = 0.03)
but not with 20 μM ADP (p = 0.18). Although there was no significant change with the VerifyNow P2Y12 assay
(p = 0.16), the change was correlated with the initial fasting value (Spearman’s rho p = 0.008). The VASP assay and WBA
varied minimally.
Conclusion: The high-fat meal did not significantly alter platelet function assessment of commonly used platelet
function tests. Greater intra-subject variability existed for the optically-dependent compared with non-optically
dependent tests.
Trial registration: NCT01307657.
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The antiplatelet agent clopidogrel is commonly pre-
scribed in the United States and around the world for
the treatment of cardiovascular disease. A number of
large, randomized clinical trials have demonstrated the
clinical efficacy of clopidogrel and the importance of its
ability to irreversibly antagonize P2Y12 receptors on
platelets [1-4]. Through inhibition of the P2Y12 receptor,
clopidogrel prevents platelet activation and aggregation,* Correspondence: pdobesh@unmc.edu
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unless otherwise stated.leading to a reduction in arterial thrombotic events, such
as myocardial infarction and stroke in patients with car-
diovascular disease.
Although clopidogrel has demonstrated clinical effi-
cacy, multiple factors contribute to high patient variabil-
ity in response to the drug, such as acute coronary
syndrome, body mass index, diabetes mellitus, adher-
ence, drug interactions, and genetics [5]. Importantly,
patients with high on-treatment platelet reactivity while
taking clopidogrel demonstrate a significant increase in
major adverse cardiac events compared to patients with
normal or decreased platelet reactivity while taking clo-
pidogrel [6]. Even with the known variability in patientl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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standard dose for all patients. Although controversial,
some evidence suggests that it may be advantageous and
cost-effective in some situations to personalize antiplate-
let therapy based on pharmacodynamic platelet assess-
ment [7]. Measuring platelet response may also help
determine if newer options for antiplatelet therapy are
more appropriate.
While other P2Y12 receptor antagonists (i.e. prasugrel
and ticagrelor) provide more potent inhibition of platelet
aggregation and reduced ischemic outcomes compared to
clopidogrel, these medications are also considerably more
expensive than generic clopidogrel and result in increased
rates of major bleeding [8,9]. While the ideal management
strategy for patients with high on-treatment platelet re-
activity is under debate, knowledge of a patient’s response
to clopidogrel has the potential to direct treatment
decisions and help improve clinical outcomes.
Currently, platelet function tests are not standardized
among institutions [10]. Furthermore, while controversy
exists regarding the ideal test to use for monitoring clo-
pidogrel therapy, even less is known about optimal test-
ing conditions [11]. One vital testing variable that has
not been well-studied for all assays is whether an ac-
curate assessment of platelet reactivity assessment de-
pends on fasting status. Data on the impact of food on
platelet function assessment are quite inconsistent in
terms of methodology and results [12].
Previous studies reveal conflicting results concerning
the effect of fasting and non-fasting conditions as well as
whether or not a high-fat meal has an effect on the as-
sessment of platelet aggregation [13-21]. Multiple factors
could explain a potential effect of a high-fat meal on
platelet aggregation assessment. For example, one physi-
ologic mechanism involves platelet interactions with tri-
glycerides and chylomicron remnants that are present in
the bloodstream after a high-fat meal. It has been sug-
gested that platelet uptake of triglycerides induces
release of platelet factor 4 and promotes platelet aggre-
gation. Additionally, it has been implied that the chylo-
micron layer on the platelet itself may interfere with the
interaction between platelets and collagen [15,22,23].
Another possibility relates to the increased cloudiness of
a lipemic sample that a high-fat meal causes. This
cloudiness of the sample possibly hinders the ability of
optically dependent assays to properly measure the ex-
tent of platelet aggregation. Regardless, most previous
studies that evaluate the effect of a high-fat meal on
platelet aggregation have used light transmittance aggre-
gometry (LTA), but other platelet assays increasingly
used in clinical practice (e.g. VerifyNow) are underrepre-
sented in current studies [11,12].
The purpose of the study herein was to determine the
influence of a high-fat meal on the assessment of plateletfunction by comparing several different assays avail-
able. With the increasing study and utilization of
platelet function testing in clinical practice, determin-
ing the appropriate testing conditions (fasting vs.
non-fasting) is critical. Furthermore, the ability to ap-
propriately assess platelet response to clopidogrel
therapy will assist in determining the optimal treat-
ment strategy for reducing ischemic outcomes and
minimizing bleeding in patients with cardiovascular
disease.Methods
The study was approved by the Ethics Committee of the
University of Nebraska Medical Center (IRB 568-10),
and all subjects demonstrated willingness to participate
through understanding and signing a consent form in
accordance with the principles of the Helsinki Declar-
ation. Twelve healthy adults not taking clopidogrel were
recruited for this prospective, single-center study. Like-
wise, all volunteers denied taking any medications that
affect platelet function for at least seven days prior to
participation in the study. Volunteers were excluded if
they had cardiovascular disease or modifiable risk factors
for cardiovascular disease (i.e., hypertension, dyslipid-
emia, diabetes mellitus, or smoking), a history of renal
or hepatic disease, illnesses requiring hospitalization or
surgery within the last three months, a history of anemia
or thrombocytopenia, currently taking proton pump
inhibitors, and/or a history of excessive bleeding or
thrombosis. Women who were pregnant were also
excluded.
Information gathered in this study was used to assess
if the presence of a high-fat meal alters the effectiveness
of several different types platelet function tests to meas-
ure platelet inhibition by clopidogrel (Figure 1). Follow-
ing a 12-hour fast, subjects were presented to the
Clinical Research Center of the University of Nebraska
Medical Center at 8:00 a.m. A baseline, fasting blood
sample was drawn, and subjects were then administered
a 600 mg dose of clopidogrel taken with water. This
loading dose of clopidogrel is commonly used in clinical
practice and achieves maximal inhibition of platelet re-
activity in two to four hours, which is sustained for at
least six hours [24]. At 12:00 p.m. (four hours after clo-
pidogrel dosing), another blood sample was drawn to
evaluate the extent of maximum platelet inhibition in
the fasting state. Following the second blood draw, sub-
jects were administered a standardized high-fat meal of
a fast food hamburger and french fries that consisted of
54 grams of fat (79% daily value), 13.5 grams of satu-
rated fat (65% daily value), 108 grams of carbohydrate
(38% daily value), 31 grams of protein, and a total caloric
content of 1,040. The third blood sample was drawn at
Figure 1 Study design.
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fat meal, to evaluate the impact of the high-fat meal on
the platelet reactivity assessment.
Complete blood counts (CBC) were obtained at the
baseline blood draw, and lipid panels were evaluated at
fasting (12:00 pm) and at 2:00 pm following the high-fat
meal. Whole blood was collected from a venous source
into anti-coagulated tubes (3.2% sodium citrate) at the
following three blood collection time points: fasting
baseline (non-medicated) (8:00 am), peak platelet inhib-
ition in the fasting state (12:00 pm), and peak platelet
inhibition after the high-fat meal (2:00 pm). Platelet
function was assessed at each time point using four dif-
ferent types of platelet inhibition assays, which included
two optically-dependent assays—LTA and the Verify-
Now® P2Y12 assay (Accumetrics, San Diego, CA)—and
two non-optically dependent assays—flow cytometry
(VASP [vasodilator-stimulated phosphoprotein ] P2Y12
assay, GP IIb/IIIa receptor activation, and CD62P ex-
pression) and whole blood impedance aggregometry.Light transmittance aggregometry
Samples of platelet-rich plasma (PRP)—obtained by cen-
trifugation of whole blood at 100 g for 15 minutes—were
incubated for three minutes in glass cuvettes and then
activated by 5 μM and 20 μM adenosine diphosphate
(ADP) in a two-well Model 700 aggregometer (Chrono-
Log) under stirring conditions. Platelet-poor plasma was
collected after centrifugation at 2400 g for 20 minutes
and placed in the reference well to establish the baseline
transmittance for each subject. Aggregometry samples
were monitored for six minutes; the area under the
curve (AUC) and amplitude were calculated using
AGGRO/LINK 8 software (version 1.2.3, Chrono-Log).VerifyNow® P2Y12 Assay
Whole blood collected in 2 mL citrated Greiner vacuette
tubes (Bio-One) was gently inverted and inserted onto
P2Y12 cartridges for analysis using the VerifyNow® de-
vice. Prior to testing, an electronic quality control was
performed daily. Data were reported as P2Y12 Reaction
Units (PRU).VASP phosphorylation assay
Flow cytometry was used to monitor phosphorylation of
VASP, an intracellular platelet protein specific for the
P2Y12 pathway, per the recommended guidelines for the
platelet VASP/P2Y12 kit (Biocytex, Marseille, France).
Whole blood was incubated with prostaglandin E1 either
alone or with ADP. The samples were fixed and then in-
cubated with a permeabilization agent and antibodies
specific to phosphorylated VASP. A separate sample was
used to test a negative isotypic control antibody. Next,
fluorochrome-labeled antibodies CD61-PE and poly-
clonal IgG- PAC1-fluorescein (FITC) were added to each
sample to label platelets and anti-VASP antibodies, re-
spectively. Platelets were identified by scatter (forward and
side) and PE fluorescence. Data were captured for at least
5,000 platelet events using the FACSCalibur system. The
geometric mean fluorescence intensity (MFI) was deter-
mined with CellQuest Pro software (Version 5.2.1, Becton,
Dickinson and Company), and the platelet reactivity index
(PRI) was calculated using the following formula: PRI =
[(MFIPGE1–MFI(PGE1+ADP)) /MFIPGE1] × 100.
Flow cytometry of PAC1 and CD62P
To further assess platelet activation by using flow cy-
tometry, the activated GP IIb/IIIa receptor was specific-
ally targeted with PAC1, and CD62P (P-selectin), which
is selectively expressed on the platelet surface after
platelet alpha granule release, as previously described
[25,26]. Whole blood was diluted 1:7 (v/v) in a modified
Tyrode’s buffer (137 mM NaCl, 2.8 mM KCL, 1 mM
MgCl2, 12 mM NaHCO3, 0.4 mM Na2HPO4, 10 mM
HEPES, 0.35% bovine serum albumin, and 5.5 mM glu-
cose; filtered, pH 7.4). Samples were incubated at 37°C
with platelet agonist or buffer as a resting control. Next,
the following fluorochrome-labeled antibodies were
added at room temperature protected from light: FITC,
CD62P-allophycocyanin (APC), and CD42b-phycoerythrin
(PE; all from Becton, Dickinson and Company). CD42b is
a surface marker for platelets. IgM-FITC and IgG-APC
were used as antibody controls. Next, samples were fixed
with 1% paraformaldehyde, diluted with buffer, and proc-
essed at the Cell Analysis Facility at the University of
Nebraska Medical Center. The samples were analyzed
Table 1 Lipid panel for the on-clopidogrel fasting and
non-fasting (post-high fat meal) states
Lipid panel Fasting Post-meal
Total Cholesterol (mg/dL) 181 ± 37 172 ± 41
Triglycerides (mg/dL) 79 ± 52 132 ± 100*
LDL-C (mg/dL) 113 ± 23 95 ± 25
HDL-C (mg/dL) 53 ± 19 50 ± 18
VLDL-C (mg/dL) 16 ± 10 21 ± 8
Cholesterol/HDL-C 3.7 ± 1.1 3.5 ± 0.8
*p = 0.002.
LDL-C = low density lipoprotein cholesterol; HDL-C = high density lipoprotein
cholesterol; VLDL-C = very low density lipoprotein cholesterol.
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identified by scatter (forward and side) and PE fluores-
cence, and data were captured for 10,000 platelet events.
Platelet activation was determined by geometric MFI.
Whole blood impedance aggregometry
Samples of whole blood (500 μL) were diluted 1:1 (v/v)
with normal saline and evaluated by impedance aggrego-
metry in a two-well Model 700 aggregometer (Chrono-
Log). Samples were pre-warmed for three minutes in the
incubation wells. Under stirring conditions (1200 rpm),
aggregometry samples were processed for six minutes
following stimulation by ADP 5 and 20 μM.
Statistical analysis
Change in measured platelet aggregation by LTA was
the primary endpoint of the study. Based on previous
data for patients treated with clopidogrel at enrollment
and retested 60 days later (SD = 14; r = 0.68) [27], the
two-sided paired t-test was used to estimate the needed
sample size. Thus, n = 12 people was an appropriate
sample size to identify a 10-unit change in LTA at 80%
power with alpha set at 0.05. The Wilcoxon Rank Sum
test was used to compare the change in platelet reactiv-
ity (between fasting and non-fasting conditions) to zero
after treatment with clopidogrel. The Spearman rho (ρ)
correlation coefficient was used to evaluate the associ-
ation between fasting platelet reactivity and the change
following a high-fat meal. Also, the statistical package
SPSS 19 (IBM) software was used, and the level of sig-
nificance was set at 0.05.
Results
The mean age of the seven males and five females re-
cruited to participate in the study was 35 ± 9 years. All
portions of the CBC profiles were within normal limits.
At the time of the fasting blood sample after treatment
with clopidogrel (12:00 pm), subjects had lipid profiles
within the normal limits (Table 1). At two hours follow-
ing intake of the standardized high-fat meal (2:00 pm),
there was a significant (67%) increase in triglycerides
from 79 mg/dL to 132 mg/dL (p = 0.002), which indi-
cates that a lipemic state had been achieved in these two
hours. The other lipid markers were similar between the
fasting and non-fasting states after treatment with clopi-
dogrel (Table 1).
Clopidogrel-induced platelet inhibition, as measured
by flow cytometry, was consistent among the fasting and
non-fasting conditions following the dose of clopidogrel
(Figure 2). For the VASP P2Y12 assay, the median PRI
for the fasting state following the clopidogrel dose was
51% (range = 8-89%), compared to 51% (range = 5-85%)
for the non-fasting state. The change in PRI between
the fasting and non-fasting conditions following theclopidogrel dose was not significant from zero (p = 0.35)
and indicated low variability. The median change in
PRI after the high-fat meal was 3% (range = 0-5%)
after adjustment for the absolute value of change.
Similarly, the results for flow cytometric analysis of
CD62P (p = 0.70 and 0.64 for ADP 5 μM and 20 μM,
respectively) and PAC1 (p = 0.27 and 0.24 for ADP
5 μM and 20 μM, respectively) support no significant
difference in platelet activation after treatment with
clopidogrel and following the high-fat meal (data not
shown).
The optically-based LTA assay demonstrated no sig-
nificant change in platelet aggregation between the fast-
ing and non-fasting states after the dose of clopidogrel
for both 5 μM (p = 0.15) and 20 μM (p = 0.068) ADP
(Figure 3). A small, but significant change was identified
in the AUC with 5 μM ADP (p = 0.034) as the median
AUC decreased from 26 (range = 4-444) to 18 (range =
6-380) from the fasting to non-fasting time points after
treatment with clopidogrel (data not shown). However, no
significant change was apparent for ADP 20 μM (p = 0.18).
Congruent with the other assays, there was no signifi-
cant change in platelet inhibition using the VerifyNow
P2Y12 assay to compare the fasting to non-fasting state
(p = 0.18) (Figure 4). Despite this finding, notable vari-
ability displayed as the fasting to non-fasting change in
PRU values ranged from -56 PRU to 28 PRU. Interest-
ingly, subjects with higher platelet reactivity in the
fasting state after treatment with clopidogrel tended to
have decreased PRU values after intake of the high-fat
meal, while those with lower platelet reactivity primar-
ily demonstrated limited changes or increased PRU
values in the non-fasting state (ρ = -0.72; p = 0.008)
(Figure 5). A similar trend was demonstrated with
LTA and 5 μM ADP (ρ = -0.53; p = 0.08) and with 20 μM
ADP (ρ = -0.54; p = 0.069), but neither reached statistical
significance.
Complete platelet inhibition was demonstrated in eight
of the 12 subjects with whole blood aggregation. There-
fore, changes in platelet aggregation due to the impact
Figure 2 Effect of a high-fat meal on the VASP P2Y12 assay. The change in platelet reactivity index from the on-treatment fasting to
non-fasting state was not significantly different from zero (p = 0.35). n = 12.
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method (data not shown).
Discussion
In this study, intake of a high-fat meal did not have a
statistically significant impact on the results of fourFigure 3 Impact of a high-fat meal on ADP-stimulated light transmitt
on-clopidogrel from the fasting state compared to following the high-fat m
of ADP, 5 μM (p = 0.15) and 20 μM (p = 0.068). n = 12.commonly used platelet function tests. The only signifi-
cant change was demonstrated in the aggregation AUC
with LTA using 5 μM ADP when comparing clopidogrel
platelet inhibition during fasting and after a high-fat
meal. Although there was no change in platelet reactivity
with the VerifyNow P2Y12 assay, a significant correlationance aggregometry. The change in maximal platelet aggregation
eal was not significantly different from zero for both concentrations
Figure 4 Impact of a high-fat meal on the VerifyNow P2Y12 assay. The change in P2Y12 Reaction Units (PRU) was not significantly different
from zero (p = 0.18). n = 12.
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and the change in platelet reactivity from fasting to after
the high-fat meal. This result suggests that subjects may
demonstrate a greater change to the high-fat meal with
high platelet reactivity while taking clopidogrel compared
to those subjects with normal clopidogrel response.
Previous research on the impact of a high-fat meal and
platelet function assessment has produced conflicting re-
sults. Some studies demonstrate an increase in baseline,
non-medicated platelet aggregation in patients after
chronic or long-term ingestion of a high-fat diet. Still,Figure 5 Correlation between fasting on-clopidogrel platelet
reactivity and the change in on-treatment platelet reactivity
after a high-fat meal for the VerifyNow P2Y12 assay. Spearman
correlation coefficients (ρ) were generated for each assay to assess
the correlation between: 1) fasting on-clopidogrel platelet reactivity
and 2) the change in platelet reactivity on-clopidogrel from the fasting
to the non-fasting state. The significant finding for the VerifyNow
P2Y12 assay (p = 0.008) suggests that subjects with high platelet
reactivity on clopidogrel may be selectively impacted by the high-fat
meal, while subjects with a normal clopidogrel response may have
more consistent results regardless whether or not a high-fat meal
is taken.the differences in platelet aggregation in these studies
are fairly minimal and are confounded by other variables
such as the type of fat ingested, patient comorbidities,
and methods for assessing platelet function [14,28,29].
For example, studies by Nordøy and associates demon-
strate an increase in platelet aggregation after acute in-
gestion of a high-fat meal. However, in these studies the
fat content of the meal reached 100 to 175 grams, pro-
vided by ingesting whipping cream [13,15]. This repre-
sents a two- to three-fold increase in fat content
compared to the more typical high-fat meal provided in
this current study. Conversely, Fuhrman and associates
were able to demonstrate an absolute increase in platelet
aggregation of 3% with acute ingestion of roughly 50
grams of fat [18]. Therefore, meaningful increases in
platelet aggregation are not demonstrated without ex-
treme fat intake.
Similar to the present study, there have also been a
number of studies that demonstrate no notable change
in platelet aggregation after acute ingestion of a high-fat
meal [16,17,19-21]. Unlike the present study, these stud-
ies did not evaluate multiple platelet aggregation assays
or have subjects receiving an antiplatelet agent. Contrary
to the studies by Nordøy and associates, the consistent
lack of an impact on platelet aggregation was demon-
strated regardless of the amount of fat in the high-fat
meal, even at levels greater than 100 grams per meal
[16,19]. There are a number of possible explanations of
why some studies report an increase in platelet aggrega-
tion and others do not. One possible explanation is that
there is actually a protective layer of chylomicrons that
form on platelets after a high-fat meal that prevent plate-
let activation [23,30]. Because most studies demonstrat-
ing an increase in platelet aggregation after a high-fat
meal evaluated washed platelets, it is possible that this
protective layer was removed in this process. There have
also been studies that show that as opposed to PRP,
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after fat intake. Another limitation to the research dem-
onstrating an increase in platelet aggregation after acute
ingestion of a high-fat meal is the use of heparin-
neutralizing activity as an indicator for plasma platelet
factor 4 levels and thereby platelet activity. Considering
that there are numerous platelet-independent factors
that have heparin neutralizing activity, the use of platelet
factor 4 as an endpoint is questionable [16]. The present
study avoids this limitation because PRP was used for
LTA and not washed platelets, as well as commonly used
measures for platelet aggregation.
Although these previous studies suggest a potential
physiologic interaction of platelets with triglycerides, the
results of the present study do not support this hypoth-
esis. Based on the four platelet function tests evaluated,
a high-fat meal was not found to significantly impact
platelet aggregation assessment. Due to the limitations
discussed in studies demonstrating an increase in plate-
let aggregation after acute ingestion of a high-fat meal,
and the larger body of evidence suggesting a lack of in-
fluence of a high-fat meal on platelet aggregation, any
variability demonstrated with the optically-dependent as-
sessment of platelet function are unlikely due to a
physiologic interaction of platelet with triglycerides. If
this type of interaction did occur, it would be expected
to be detected as changes in platelet aggregation in the
VASP assay in the present study. Instead, the exceptional
consistency of the VASP results before and after the
high-fat meal disputes this possibility. Although there
was not an impact of a high-fat meal on most platelet
function tests used in this study, the optically dependent
tests demonstrated more intra-subject variability com-
pared to the non-optically dependent test.
The impact of a high-fat meal with clopidogrel has
been evaluated in other studies with different designs
compared to the present study [31,32]. For example, one
of these studies only evaluated the impact of the high-fat
meal on the bioavailability and pharmacokinetics of clo-
pidogrel [31]. While this study did not find a significant
change in the Cmax, Tmax, or AUC for clopidogrel, this
study also did not evaluate the influence of the high-fat
meal on the pharmacodynamics of clopidogrel. The
study by Hurbin and associates found a non-significant
4.7% difference in maximal platelet aggregation before
and after a high-fat meal as assessed by LTA with 5 μM
ADP. Unlike the present study, the evaluations of the
non-fasting and fasting states were not compared on the
same day two hours apart, but instead they were com-
pared two weeks apart. Their study also evaluated a
loading dose of clopidogrel 300 mg compared to the
commonly used dose of 600 mg in the present study.
The present study significantly adds to these data be-
cause the more commonly used VerifyNow® assay andVASP assay were evaluated, as well as the timely impact
of a high-fat meal to assessment of platelet aggregation.
Based on a thorough review of the literature, the
present study is the first to evaluate the impact of a high-
fat meal on clopidogrel-induced platelet aggregation with
both optically dependent and non-optically dependent
assays. Subjects were evaluated at baseline and after re-
ceiving a 600 mg dose of clopidogrel, which provides
more clinically useful relevant information compared to
evaluating volunteers not taking antiplatelet therapy. A
600 mg loading dose was used because it is commonly
used in clinical practice and provides the fastest and
most-potent platelet inhibition with the use of clopido-
grel [24]. Therefore, the present study adds important in-
formation about the lack of impact of a high-fat meal on
clopidogrel-induced platelet aggregation measurement
with some of the most commonly used assays.
Even though the present study provides novel informa-
tion, inevitably there are still limitations. For one, the
sample size in the present study was only calculated for
LTA, thus the study may not have the power to detect
differences in the other tests. Another limitation to the
study is that it does not evaluate the effect of a high-fat
meal on all platelet function assays such as multiplate
analyzer and the thromboelastograph, of which neither
were used in the present study. We also did not specific-
ally collect data on body weight or body mass index for
the subjects, which can be associated with poor respon-
siveness to clopidogrel. Finally, this study included
young healthy volunteers instead of patients with known
coronary artery disease or immediately after an acute
coronary syndrome. While this is not expected to have
had an impact on the results from the study, patients
with active atherosclerotic disease are known to have
higher levels of platelet aggregation.
Conclusion
In the future, patients taking the P2Y12 antagonist clopi-
dogrel could undergo an assessment of platelet function
to determine appropriate dose or need for an alternative
agent. It is imperative that the appropriate platelet assay
is utilized under the appropriate conditions. In the
present study, the intake of a high-fat meal did not sig-
nificantly alter platelet function assessment of commonly
used platelet function tests. Therefore, these data sug-
gest that there is not a need to avoid a high-fat meal be-
fore platelet aggregation assessment. There was more
intra-subject variability with the optically dependent
compared with non-optically dependent platelet function
tests, which will require further study.
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